Brief: Ardelyx Chose Not To Apply To Include Xphozah In CMS End-Stage Renal Disease Prospective Payment System Transitional Drug Add-On Payment Adjustment
02/07/2024 12:06
July 2 (Reuters) - Ardelyx Inc ARDX.O :
* ARDELYX: CHOSE NOT TO APPLY TO INCLUDE XPHOZAH IN CMS
END-STAGE
RENAL DISEASE PROSPECTIVE PAYMENT SYSTEM TRANSITIONAL DRUG
ADD-ON PAYMENT ADJUSTMENT
Source text for Eikon: ID:n0001628280-24-030708
Further company coverage: ARDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ardelyx
See all newsArdelyx, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ardelyx says Q2 product revenue at record high but IBSRELA revenue below expectations
Brief: Ardelyx Q2 Product Sales USD 118.129 Million
Ardelyx Q1 product revenue rises 38% on IBSRELA growth
Brief: Ardelyx Q1 Product Sales USD 93.373 Million